Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.

Alkayyali T., Qutranji L., Kaya E., Bakir A., Yilmaz Y.

Acta diabetologica, cilt.57, sa.5, ss.613-618, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57 Sayı: 5
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1007/s00592-019-01467-7
  • Dergi Adı: Acta diabetologica
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.613-618
  • Anahtar Kelimeler: Non-alcoholic fatty liver disease, Fibrosis scores, Advanced fibrosis, Type 2 diabetes mellitus, Screening, SCORING SYSTEM, NAFLD, DIAGNOSIS
  • Marmara Üniversitesi Adresli: Evet

Özet

BACKGROUND/AIM:

Simple noninvasive fibrosis scores based on routine blood tests have been increasingly investigated as screening tools in different clinical settings. Here, we sought to examine whether the Fibrosis-4 Index (FIB-4) and the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) could perform differently in diabetic versus non-diabetic patients with biopsy-proven NAFLD.

METHODS:

We examined 349 patients with biopsy-proven NAFLD (166 with type 2 diabetes and 183 without). Patients with FIB-4 scores < 1.3 and  > 2.67 or NFS scores < - 1.455 and  > 0.676 were considered at low and high risk of advanced fibrosis, respectively.

RESULTS:

A FIB-4 cutoff value of 1.3-which denotes a low risk of advanced fibrosis-had a specificity of 67% in patients with diabetes and 69% in those without. Conversely, a FIB-4 cutoff value of 2.67-which denotes a high risk of advanced fibrosis-had a sensitivity of 22% in patients with diabetes and 0% in those without. NFS performed similar to FIB-4.

CONCLUSION:

Both FIB-4 and NFS scores have an acceptable clinical utility in the exclusion of advanced fibrosis in patients with NAFLD, regardless of the presence of type 2 diabetes. However, their usefulness in identifying advanced fibrosis is limited-especially in the absence of diabetes.